| Abstract: |
Cell-cycle inhibition is a new standard-of-care therapy in estrogen-receptor-positive metastatic breast cancer (MBC). The rapid integration of cyclin-dependent kinase (CDK) 4/6 inhibitors into mainstream clinical practice has led to many important investigations into biomarkers of response, mechanisms of resistance, sequencing of therapies, the role of other CDK4/6 inhibitors, and usage in other breast cancer subtypes. Here, we review the current state of palbociclib, ribociclib, and abemaciclib as CDK4/6 inhibitors in MBC, with particular attention to ongoing clinical trials in breast cancer. |
